RBC Capital Maintains Outperform on Evolent Health, Lowers Price Target to $42
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Sean Dodge has maintained an Outperform rating on Evolent Health (NYSE:EVH) but reduced the price target from $44 to $42.

November 28, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
RBC Capital analyst reaffirms Outperform rating on Evolent Health but lowers price target from $44 to $42.
The reduction in price target by RBC Capital may have a neutral to slightly negative short-term impact on EVH's stock price as it suggests a lower valuation than previously estimated. However, maintaining the Outperform rating indicates a continued positive outlook on the company, which could balance out the negative sentiment from the target reduction.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100